Clinical trial
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
NCT00086203 · Point Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00086203 |
|---|---|
| Title | Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) |
| Lead sponsor | Point Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Talabostat mesylate (PT-100) tablets, Rituximab |
| Completion | Sep 1, 2007 |
| First posted | Jun 29, 2004 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: